iScience (Dec 2023)

Airway epithelial cells and macrophages trigger IL-6-CD95/CD95L axis and mediate initial immunopathology of COVID-19

  • Thais F.C. Fraga-Silva,
  • Ualter G. Cipriano,
  • Marcilio J. Fumagalli,
  • Giseli F. Correa,
  • Carlos A. Fuzo,
  • Douglas dos-Santos,
  • Fabiola L.A.C. Mestriner,
  • Christiane Becari,
  • Andrea Teixeira-Carvalho,
  • Jordana Coelho-dos-Reis,
  • Mayra G. Menegueti,
  • Luiz T.M. Figueiredo,
  • Larissa D. Cunha,
  • Olindo A. Martins-Filho,
  • Marcelo Dias-Baruffi,
  • Maria Auxiliadora-Martins,
  • Rita C. Tostes,
  • Vania L.D. Bonato

Journal volume & issue
Vol. 26, no. 12
p. 108366

Abstract

Read online

Summary: Airway epithelial cells (AEC) infected with SARS-CoV-2 may drive the dysfunction of macrophages during COVID-19. We hypothesized that the direct interaction of AEC with macrophages mediated by CD95/CD95L or indirect interaction mediated by IL-6 signaling are key steps for the COVID-19 severe acute inflammation. The interaction of macrophages with apoptotic and infected AEC increased CD95 and CD163 expression, and induced macrophage death. Macrophages exposed to tracheal aspirate with high IL-6 levels from intubated patients with COVID-19 or to recombinant human IL-6 exhibited decreased HLA-DR expression, increased CD95 and CD163 expression and IL-1β production. IL-6 effects on macrophages were prevented by both CD95/CD95L antagonist and by IL-6 receptor antagonist and IL-6 or CD95 deficient mice showed significant reduction of acute pulmonary inflammation post-infection. Our findings show a non-canonical CD95L-CD95 pathway that simultaneously drives both macrophage activation and dysfunction and point to CD95/CD95L axis as therapeutic target.

Keywords